From case studies to common practice: a roadmap for precision oncology in Europe (Guest blog)
Cancer is currently the second leading cause of death in Europe and is projected to become the number one killer by 2035. Precision oncology, which customizes cancer care to the genetic profile of an individual tumor, offers hope for patients. By using molecular and genomic information to guide treatment decisions, precision oncology can help identify patients most likely to benefit from specific therapies, reduce exposure to ineffective treatments and unnecessary side effects, and support more efficient use of healthcare resources. Precision oncology is moving beyond specialist centers to be part of multidisciplinary cancer care at cancer centers across Europe.
However, these advances are not reaching all European patients equally. Awareness of genomic testing varies sharply between countries and even within them. Laboratories may meet high technical standards while the pathway from a test result to an accessible, reimbursed therapy remains unclear. And even when a biomarker test and its matched treatment are both validated, separate budgets, timelines and approval processes for diagnostics and medicines can delay routine access for years.
Ensuring patients have access to genomic testing, molecular tumor boards and biomarker-guided treatments require awareness across stakeholders, a well-functioning infrastructure and trained workforce and adequate funding and reimbursement. The EU has promising areas of world-class precision oncology, but too many patients are still missing out.
To help improve the concrete implementation of precision oncology, addressing the issues identified on the ground and disseminating best practices, the Precision Oncology workstream of EFPIA’s Oncology Platform developed a comprehensive white paper titled "Advancing precision oncology treatment and testing across Europe". The white paper was built with the input of clinicians, regional health authorities, patient representatives, health economists, academics and industry experts via interviews, bilateral meetings and a workshop.